Jazalde
Forumer storico
ne ho poche altrimenti avrei venduto e passato su Vanda o altro
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
viralic
Forumer storico
icOx SA Raises €4 Million Through Convertible and Ordinary Bond Issuance
Oggi 07:30 - RSF
NicOx SA has announced the completion of a new debt financing, raising €3 million through the issuance of convertible bonds and an additional €1 million in ordinary bonds, the latter being subject to certain conditions precedent. The convertible bonds were issued to European institutional investors, including Vester Finance, and were carried out under the delegation granted by shareholders at the General Meeting on June 27, 2025. The convertible bonds do not bear interest or guarantees and will be redeemed at 100% of their nominal value at maturity if not converted. Full details, including risk factors, are available on Nicox's website: www.nicox.com.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001157520-en) on January 05, 2026, and is solely responsible for the information contained therein.
Oggi 07:30 - RSF
NicOx SA has announced the completion of a new debt financing, raising €3 million through the issuance of convertible bonds and an additional €1 million in ordinary bonds, the latter being subject to certain conditions precedent. The convertible bonds were issued to European institutional investors, including Vester Finance, and were carried out under the delegation granted by shareholders at the General Meeting on June 27, 2025. The convertible bonds do not bear interest or guarantees and will be redeemed at 100% of their nominal value at maturity if not converted. Full details, including risk factors, are available on Nicox's website: www.nicox.com.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001157520-en) on January 05, 2026, and is solely responsible for the information contained therein.
viralic
Forumer storico
-Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
Oggi 07:30 - RSF
For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getn...ers.com:20260105:nGNEwjlwS&default-theme=true
Press Release
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
* Company’s position strengthened, enabling flexibility in strategic discussions * All Kreos Capital secured debt repaid using cash on hand * Unsecured bond financing of up to €4 million concluded with partner and shareholder, Vester Finance * Cash runway extended beyond 2027
January 5, 2026 – release at 7:30 am CET Sophia Antipolis, France
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced repayment of all secured debt and extension of its cash runway beyond 2027 with an additional unsecured financing.
“The full repayment of our debt to funds and accounts managed by Kreos Capital announced today removes a number of obligations on the Company as a result of the security interests granted over Nicox’s assets. In the last 24 months, we have demonstrated our ability to meet our timelines and fulfil our obligations, and we appreciate the support that our long-term debtholders have given us,” said Gavin Spencer, Chief Executive Officer of Nicox. “To reinforce our cash position and better manage our resources, we have taken the opportunity to continue our successful collaboration with our financing partner and shareholder, Vester Finance. Based on our current cash on hand and the current timelines, this additional financing of up to €4 million extends our cash runway beyond the end of 2027. We are now in a healthier and significantly stronger position to navigate the future, including in our strategic discussions.”
Nicox has fully repaid all outstanding debt with funds and accounts managed by Kreos Capital(1) using existing cash at 31 December 2025, thereby releasing all security guarantees over Nicox assets and terminating the right for Kreos Capital to appoint an Observer to the Board of Directors. This transaction coincides with raising new financing through the issuance of bonds to European investors, including Vester Finance, a current financing partner and established institutional investor. This financing consists of an issue of €3 million of convertible bonds and €1 million of ordinary bonds (subject to certain conditions precedent) and extends the Company’s cash runway beyond the end of 2027. This financing does not have any guarantee or security interest associated with it.
Nicox is continuing to evaluate future strategic growth opportunities, including collaborations or business combinations.
Key Future Milestones
* NCX 470 NDA submission in the United States: expected in summer 2026, based on a pre-NDA meeting, which is scheduled in Q1 2026 * NCX 470 NDA submission in China: expected shortly after submission in the U.S.
* NCX 470 Phase 3 clinical program in Japan: initiated in summer 2025. Managed and financed by Kowa.
Cash Runway
Based on the expected upcoming milestones, including the submission of an NCX 470 New Drug Application in the U.S. and a standard review period of 12 months, the financing announced today and the repayment of the Kreos Capital debt, the Company believes that its current activities are financed to beyond the end of 2027. The Company remains committed to cost control and optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway.
Potential proceeds from existing warrants and the €1 million additional bond financing, subject to certain conditions precedent, are not included in the above cash runway calculation.
Full Repayment of the Kreos Capital Debt
Nicox originally subscribed to a secured long-term debt with funds and accounts managed by Kreos Capital totalling €20 million in 2019. Today’s payment reimburses the remaining outstanding balance of that debt in totality.
In accordance with the amendment announced (https://www.globenewswire.com/Track...9czkJW_Y7MWA55Pm0hjlIwCOsEUEc7mh0JCAD4amD2Q==) on 14 October 2024, Kreos Capital retains 17 warrants giving the right to acquire 400,000 shares per warrant in Nicox at €0.25, which can be exercised until 14 October 2036.
As of 31 December 2025, Nicox’s remaining debt amounted to €0.3 million, consisting entirely of the outstanding balance of a COVID loan, which will be repaid from cash in hand by the end of August 2026.
Oggi 07:30 - RSF
For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getn...ers.com:20260105:nGNEwjlwS&default-theme=true
Press Release
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
* Company’s position strengthened, enabling flexibility in strategic discussions * All Kreos Capital secured debt repaid using cash on hand * Unsecured bond financing of up to €4 million concluded with partner and shareholder, Vester Finance * Cash runway extended beyond 2027
January 5, 2026 – release at 7:30 am CET Sophia Antipolis, France
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced repayment of all secured debt and extension of its cash runway beyond 2027 with an additional unsecured financing.
“The full repayment of our debt to funds and accounts managed by Kreos Capital announced today removes a number of obligations on the Company as a result of the security interests granted over Nicox’s assets. In the last 24 months, we have demonstrated our ability to meet our timelines and fulfil our obligations, and we appreciate the support that our long-term debtholders have given us,” said Gavin Spencer, Chief Executive Officer of Nicox. “To reinforce our cash position and better manage our resources, we have taken the opportunity to continue our successful collaboration with our financing partner and shareholder, Vester Finance. Based on our current cash on hand and the current timelines, this additional financing of up to €4 million extends our cash runway beyond the end of 2027. We are now in a healthier and significantly stronger position to navigate the future, including in our strategic discussions.”
Nicox has fully repaid all outstanding debt with funds and accounts managed by Kreos Capital(1) using existing cash at 31 December 2025, thereby releasing all security guarantees over Nicox assets and terminating the right for Kreos Capital to appoint an Observer to the Board of Directors. This transaction coincides with raising new financing through the issuance of bonds to European investors, including Vester Finance, a current financing partner and established institutional investor. This financing consists of an issue of €3 million of convertible bonds and €1 million of ordinary bonds (subject to certain conditions precedent) and extends the Company’s cash runway beyond the end of 2027. This financing does not have any guarantee or security interest associated with it.
Nicox is continuing to evaluate future strategic growth opportunities, including collaborations or business combinations.
Key Future Milestones
* NCX 470 NDA submission in the United States: expected in summer 2026, based on a pre-NDA meeting, which is scheduled in Q1 2026 * NCX 470 NDA submission in China: expected shortly after submission in the U.S.
* NCX 470 Phase 3 clinical program in Japan: initiated in summer 2025. Managed and financed by Kowa.
Cash Runway
Based on the expected upcoming milestones, including the submission of an NCX 470 New Drug Application in the U.S. and a standard review period of 12 months, the financing announced today and the repayment of the Kreos Capital debt, the Company believes that its current activities are financed to beyond the end of 2027. The Company remains committed to cost control and optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway.
Potential proceeds from existing warrants and the €1 million additional bond financing, subject to certain conditions precedent, are not included in the above cash runway calculation.
Full Repayment of the Kreos Capital Debt
Nicox originally subscribed to a secured long-term debt with funds and accounts managed by Kreos Capital totalling €20 million in 2019. Today’s payment reimburses the remaining outstanding balance of that debt in totality.
In accordance with the amendment announced (https://www.globenewswire.com/Track...9czkJW_Y7MWA55Pm0hjlIwCOsEUEc7mh0JCAD4amD2Q==) on 14 October 2024, Kreos Capital retains 17 warrants giving the right to acquire 400,000 shares per warrant in Nicox at €0.25, which can be exercised until 14 October 2036.
As of 31 December 2025, Nicox’s remaining debt amounted to €0.3 million, consisting entirely of the outstanding balance of a COVID loan, which will be repaid from cash in hand by the end of August 2026.
PIZZODIGINO
Pacifico
Bisogna ammettere che la Nicox ha la pellaccia dura; un'altra società al suo posto sarebbe già fallita.
viralic
Forumer storico
convertibile in azioni....senza interessi e senza garanzie. Il prezzo ? quello corrente quando vorranno convertire le obbligazioni in azioni...non sono warrant. Dunque non propriamente un finanziamento ma un investimento.
Jazalde
Forumer storico
Ok chiaro,grazie
